This review discusses the development and uses of imatinib mesylate, a protein tyrosine
kinase inhibitor useful in the treatment of chronic myelogenous leukemia and …

Imatinib mesylate, also known as ST1571 or CGP57148, is a competitive inhibitor of a few
tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor …

Abstract Purpose: Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ) is a receptor
tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug …

Abstract▴ Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the
tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Abstract Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …

Background Constitutive activation of KIT receptor tyrosine kinase is critical in the
pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine …

Summary Imatinib mesylate (Gleevec®/Glivec®, Novartis, Basel, Switzerland), formerly
called STI571, is a specific and potent inhibitor of the BCR‐ABL tyrosine kinase, the …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the mechanism of action (ie, the molecular targets) of the anticancer drug imatinib …

The aim of this study was to assess the antitumour response and time to progression (TTP)
of patients treated with imatinib mesylate (Glivec®, Gleevec™, formerly STI-571) who had …